Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for cardiovascular disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Intensive diabetes treatment and cardiovasculardisease in patients with type 1 diabetes. Intensive diabetes therapy aimed at achieving near normoglycemia reduces the risk of microvascular and neurologic complications of type 1 diabetes. We studied whether the use of intensive therapy as compared with conventional therapy during the Diabetes Control and Complications Trial (DCCT) affected the long-term incidence of cardiovascular disease.The DCCT randomly assigned 1441 patients with type 1 (...) diabetes to intensive or conventional therapy, treating them for a mean of 6.5 years between 1983 and 1993. Ninety-three percent were subsequently followed until February 1, 2005, during the observational Epidemiology of Diabetes Interventions and Complications study. Cardiovasculardisease (defined as nonfatal myocardial infarction, stroke, death from cardiovasculardisease, confirmed angina, or the need for coronary-artery revascularization) was assessed with standardized measures and classified
Vitamin E in the primary prevention of cardiovasculardisease and cancer: the Women's Health Study: a randomized controlled trial. Basic research provides plausible mechanisms and observational studies suggest that apparently healthy persons, who self-select for high intakes of vitamin E through diet or supplements, have decreased risks of cardiovasculardisease and cancer. Randomized trials do not generally support benefits of vitamin E, but there are few trials of long duration among (...) initially healthy persons.To test whether vitamin E supplementation decreases risks of cardiovasculardisease and cancer among healthy women.In the Women's Health Study conducted between 1992 and 2004, 39 876 apparently healthy US women aged at least 45 years were randomly assigned to receive vitamin E or placebo and aspirin or placebo, using a 2 x 2 factorial design, and were followed up for an average of 10.1 years.Administration of 600 IU of natural-source vitamin E on alternate days.Primary outcomes
Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. Observational studies have shown that psychosocial factors are associated with increased risk for cardiovascular morbidity and mortality, but the effects of behavioral interventions on psychosocial and medical end points remain uncertain.To determine the effect of 2 behavioral programs, aerobic exercise training and stress management (...) training, with routine medical care on psychosocial functioning and markers of cardiovascular risk.Randomized controlled trial of 134 patients (92 male and 42 female; aged 40-84 years) with stable ischemic heart disease (IHD) and exercise-induced myocardial ischemia. Conducted from January 1999 to February 2003.Routine medical care (usual care); usual care plus supervised aerobic exercise training for 35 minutes 3 times per week for 16 weeks; usual care plus weekly 1.5-hour stress management training
A systematic review of the outcomes of cardiovascular exercise programs for people with Down syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Risk indices associated with the insulin resistance syndrome, cardiovasculardisease, and possible protection with yoga: a systematic review Risk indices associated with the insulin resistance syndrome, cardiovasculardisease, and possible protection with yoga: a systematic review Risk indices associated with the insulin resistance syndrome, cardiovasculardisease, and possible protection with yoga: a systematic review Innes K E, Bourguignon C, Taylor A G CRD summary The review determined (...) the efficacy of yoga on anthropometric and physiologic indices of cardiovasculardisease risk and related end points. Based on a large number of diverse primary studies of limited quality, the authors are justified in concluding that further well-conducted research is necessary. Authors' objectives To determine the efficacy of yoga on anthropometric and physiologic indices (such as insulin resistance syndrome, IRS) of cardiovasculardisease (CVD) risk and on related end points. Searching MEDLINE, IndMED
EDTA chelation therapy for cardiovasculardisease: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Risk of morbidity and mortality from cardiovasculardisease following radiotherapy for childhood cancer: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project Coronary calcium independently predicts incident premature coronary heart disease over (...) for ethic minorities as well. Prospective clinical trials with accurate cost measurements are also necessary to achieve more robust cost-effectiveness results. Source of funding None stated. Bibliographic details Taylor A J, Bindeman J, Feuerstein I, Cao F, Brazaitis M, O'Malley P G. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. Journal
Evaluating national guidelines for prevention of cardiovasculardisease in primary care Evaluating national guidelines for prevention of cardiovasculardisease in primary care Evaluating national guidelines for prevention of cardiovasculardisease in primary care Marshall T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined national guidelines for the prevention of cardiovasculardisease (CVD) in primary care. The guidelines for the USA, Canada, UK, New Zealand (NZ) and Australia were analysed. Each guideline identified three principal drug intervention areas. These were the lowering of blood pressure with antihypertensive drugs, aspirin, and the lowering of cholesterol with drugs. Type of intervention
The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovasculardisease by more than 75%. Although the Polypill concept (proposed in 2003) is promising in terms of benefits for cardiovascular risk management, the potential costs and adverse effects are its main pitfalls. The objective of this study was to identify a tastier and safer alternative to the Polypill: the Polymeal.Data on the ingredients of the Polymeal were taken from the literature (...) . The evidence based recipe included wine, fish, dark chocolate, fruits, vegetables, garlic, and almonds. Data from the Framingham heart study and the Framingham offspring study were used to build life tables to model the benefits of the Polymeal in the general population from age 50, assuming multiplicative correlations.Combining the ingredients of the Polymeal would reduce cardiovasculardisease events by 76%. For men, taking the Polymeal daily represented an increase in total life expectancy of 6.6 years
Taking glucocorticoids by prescription is associated with subsequent cardiovasculardisease. Glucocorticoids have adverse systemic effects, including obesity, hypertension, and hyperglycemia, that may predispose to cardiovasculardisease. The effect of glucocorticoid use on cardiovasculardisease has not been quantified.To test the hypothesis that users of exogenous glucocorticoids have an increased risk for cardiovascular disease.A cohort study using a record linkage database.Tayside, Scotland (...) , United Kingdom.68,781 glucocorticoid users and 82,202 nonusers without previous hospitalization for cardiovasculardisease who were studied between 1993 and 1996.The average daily dose of glucocorticoid exposure during follow-up was categorized as low (inhaled, nasal, and topical only), medium (oral, rectal, or parenteral <7.5 mg of prednisolone equivalent), or high (> or =7.5 mg of prednisolone equivalent). Poisson regression model, sensitivity analysis, and propensity score methods were used
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. End-stage renal disease substantially increases the risks of death, cardiovasculardisease, and use of specialized health care, but the effects of less severe kidney dysfunction on these outcomes are less well defined.We estimated the longitudinal glomerular filtration rate (GFR) among 1,120,295 adults within a large, integrated system of health care delivery in whom serum creatinine had been measured (...) between 1996 and 2000 and who had not undergone dialysis or kidney transplantation. We examined the multivariable association between the estimated GFR and the risks of death, cardiovascular events, and hospitalization.The median follow-up was 2.84 years, the mean age was 52 years, and 55 percent of the group were women. After adjustment, the risk of death increased as the GFR decreased below 60 ml per minute per 1.73 m2 of body-surface area: the adjusted hazard ratio for death was 1.2
Association of hemoglobin A1c with cardiovasculardisease and mortality in adults: the European prospective investigation into cancer in Norfolk. Increasing evidence suggests a continuous relationship between blood glucose concentrations and cardiovascular risk, even below diagnostic threshold levels for diabetes.To examine the relationship between hemoglobin A1c, cardiovasculardisease, and total mortality.Prospective population study.Norfolk, United Kingdom.4662 men and 5570 women who were 45 (...) to 79 years of age and were residents of Norfolk.Hemoglobin A1c and cardiovasculardisease risk factors were assessed from 1995 to 1997, and cardiovasculardisease events and mortality were assessed during the follow-up period to 2003.In men and women, the relationship between hemoglobin A1c and cardiovasculardisease (806 events) and between hemoglobin A1c and all-cause mortality (521 deaths) was continuous and significant throughout the whole distribution. The relationship was apparent in persons
] and Postmenopausal Estrogen-Progestin Intervention questionnaire [PEPI-Q] scores) with coronary artery disease (CAD) risk factors, angiographic CAD, and adverse cardiovascular (CV) events in women evaluated for suspected myocardial ischemia.The National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) is a multicenter prospective cohort study. From 1996-2000, 936 women were enrolled at 4 US academic medical centers at the time of clinically indicated coronary angiography (...) Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women. Individual contributions of obesity and physical fitness (physical activity and functional capacity) to risk of coronary heart disease in women remain unclear.To investigate the relationships of measures of obesity (body mass index [BMI], waist circumference, waist-hip ratio, and waist-height ratio) and physical fitness (self-reported Duke Activity Status Index [DASI
of adverse events was noted in the atorvastatin group.Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovasculardisease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol. No justification is available for having a particular threshold level of LDL-cholesterol as the sole arbiter of which patients with type 2 diabetes should receive statins. The debate about whether all people with this disorder warrant statin treatment should now (...) Primary prevention of cardiovasculardisease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Type 2 diabetes is associated with a substantially increased risk of cardiovasculardisease, but the role of lipid-lowering therapy with statins for the primary prevention of cardiovasculardisease in diabetes is inadequately defined. We aimed to assess the effectiveness of atorvastatin 10 mg daily
2004LancetControlled trial quality: predicted high
Parental cardiovasculardisease as a risk factor for cardiovasculardisease in middle-aged adults: a prospective study of parents and offspring. Whether parental cardiovasculardisease confers increased risk independent of other risk factors remains controversial. Prior studies relied on offspring report, without complete validation of parental events.To determine whether parental cardiovasculardisease predicts offspring events independent of traditional risk factors, using a prospective (...) design for both parents and offspring, and uniform criteria to validate events.Inception cohort study.Framingham Heart Study, a US population-based epidemiologic cohort begun in 1948 with the offspring cohort established in 1971.All Framingham Offspring Study participants (aged > or =30 years) who were free of cardiovasculardisease and both parents in the original Framingham cohort.We examined the association of parental cardiovasculardisease with 8-year risk of offspring cardiovasculardisease
were low because the prevalence of these conditions was low in parents. If patients were more aware of their parents' medical illnesses, they might be able to estimate their risk for disease more accurately and perhaps motivate themselves to follow a healthy lifestyle. (...) Accuracy of offspring reports of parental cardiovasculardisease history: the Framingham Offspring Study. Family history is used to infer the risk for heart disease; however, little is known about the accuracy of family history reports.To examine the accuracy of offspring reports of parental cardiovascular disease.Validation study.Framingham Heart Study.Offspring participants of the multigenerational Framingham Heart Study with both parents in the original cohort.791 men and 837 women (mean age
Adapting your practice: treatment and recommendations for homeless patients with cardiovasculardiseases. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines
Effects of omega-3 fatty acids on cardiovasculardisease Effects of omega-3 fatty acids on cardiovasculardisease Effects of omega-3 fatty acids on cardiovasculardisease Wang C, Chung M, Lichtenstein A, Balk E, Kupelnick B, DeVine D, Lawrence A, Lau J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wang C, Chung M, Lichtenstein A, Balk E (...) , Kupelnick B, DeVine D, Lawrence A, Lau J. Effects of omega-3 fatty acids on cardiovasculardisease. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 94. 2004 Authors' objectives As the first of a 3-part report on this topic, we analyzed relevant nutrition databases to describe the intake levels of various omega-3 fatty acids in the US population. We also performed a systematic review of the literature to assess the benefits of omega-3 fatty acid
Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovasculardisease Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovasculardisease Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovasculardisease Balk E, Chung M, Lichtenstein A, Chew P, Kupelnick B, Lawrence A, DeVine D, Lau J Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Balk E, Chung M, Lichtenstein A, Chew P, Kupelnick B, Lawrence A, DeVine D, Lau J. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovasculardisease. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 93. 2004 Authors' objectives As the second of a 3-part report on this topic, we